Shepherding Therapeutic Cancer Vaccines through Clinical Development | Page 10

www.clinipace.com

References
American Cancer Society. Cancer Facts and Figures 2011. Available at:
http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cance
r-facts-figures-2011. Accessed July 6, 2011.
BCC Research. Therapeutic Vaccines: The Global Market. Available at:
http://www.bccresearch.com/report/therapeutic-vaccines-bio052b.html.
Accessed July 1, 2011
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for
castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human
cancer genomes. Nature. 2007;446(7132):153-8.
Hanna MG, Hoover HC, Pinedo HM, et al. Active specific immunotherapy with
autologous tumor cell vaccines for stage II colon cancer. Hum Vaccin.
2006;2(4):185-91.
U.S Food and Drug Administration. Guidance for Industry: Clinical
Considerations for Therapeutic Cancer Vaccines. September 2009. Available at:
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInf
ormation/Guidances/Vaccines/ucm182443.htm. Accessed June 28, 2011.
Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer
immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-97.
Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast
and colorectal cancers. Science. 2007;318(5853):1108-13.

Page | 10

©2011 Clinipace Worldwide, Inc. All rights reserved.